HCM
PBYI icon

Highlander Capital Management’s Puma Biotechnology PBYI Stock Holding History

Highlander Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,000
Closed -$39K – 704
2019
Q1 		$39K Buy
+1,000
New +$30.5K 0.02% 358
2017
Q4 		– Sell
-500
Closed -$60K – 752
2017
Q3 		$60K Hold
500
– – 0.05% 320
2017
Q2 		$44K Buy
+500
New +$28K 0.03% 370

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Highlander Capital Management's PBYI Position: Q2 2019 in Review

Highlander Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 1,000 shares — an estimated $39K sold.

Highlander Capital Management first reported a position in PBYI in Q2 2017 and held it in 3 quarters. The position peaked at $60K in Q3 2017. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

  • Highlander Capital Management reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
  • Highlander Capital Management sold 1,000 Puma Biotechnology shares in Q2 2019, an estimated $39K.
  • Highlander Capital Management first reported a position in Puma Biotechnology in Q2 2017 and held it in 3 quarters.
  • Highlander Capital Management's Puma Biotechnology position peaked at $60K in Q3 2017.
  • 139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Highlander Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.